Literature DB >> 7846822

A comparison of canine distemper vaccine and measles vaccine for the prevention of canine distemper in young puppies.

W S Chalmers, W Baxendale.   

Abstract

Two groups of six-week-old beagle puppies were vaccinated with either high titre canine distemper virus or human measles virus, a third group remaining unvaccinated. All the puppies were subsequently challenged by the nasopharyngeal route at 10 weeks old with the virulent Snyder-Hill strain of canine distemper. Severe clinical signs were observed in 90 per cent of the unvaccinated dogs but both groups of vaccinated dogs survived the challenge. High temperatures were recorded in 20 per cent of the measles vaccinates and abdominal petechial rashes were observed in 60 per cent of them. The only clinical signs observed in the puppies vaccinated with distemper virus were transient rashes in 20 per cent of the group. The high titre canine distemper vaccine stimulated a humoral response quickly in 78 per cent of the puppies in the presence of maternally derived antibody and protected them against challenge with the virulent Snyder-Hill strain of distemper virus. The remaining dogs responded sluggishly but were still protected against challenge. The results of field surveys showed that 95 per cent of young puppies with different levels of maternally derived antibodies responded to the distemper component in a vaccine also containing canine parvovirus. No incompatibility was observed between the two components.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7846822     DOI: 10.1136/vr.135.15.349

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  9 in total

1.  Antibody titers for canine parvovirus type-2, canine distemper virus, and canine adenovirus type-1 in adult household dogs.

Authors:  Masayuki Taguchi; Kazuhiko Namikawa; Takuya Maruo; Kensuke Orito; Jonathan Lynch; Hiroeki Sahara
Journal:  Can Vet J       Date:  2011-09       Impact factor: 1.008

2.  Effects of body weight on antibody titers against canine parvovirus type 2, canine distemper virus, and canine adenovirus type 1 in vaccinated domestic adult dogs.

Authors:  Masayuki Taguchi; Kazuhiko Namikawa; Takuya Maruo; Miyoko Saito; Jonathan Lynch; Hiroeki Sahara
Journal:  Can J Vet Res       Date:  2012-10       Impact factor: 1.310

3.  Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection.

Authors:  C B Stephensen; J Welter; S R Thaker; J Taylor; J Tartaglia; E Paoletti
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

Review 4.  Tropism and molecular pathogenesis of canine distemper virus.

Authors:  Santiago Rendon-Marin; Renata da Fontoura Budaszewski; Cláudio Wageck Canal; Julian Ruiz-Saenz
Journal:  Virol J       Date:  2019-03-07       Impact factor: 4.099

Review 5.  Canine and Phocine Distemper Viruses: Global Spread and Genetic Basis of Jumping Species Barriers.

Authors:  Judith M Kennedy; J A Philip Earle; Shadia Omar; Hani'ah Abdullah; Ole Nielsen; Melody E Roelke-Parker; S Louise Cosby
Journal:  Viruses       Date:  2019-10-14       Impact factor: 5.048

Review 6.  Overview of new vaccines and technologies.

Authors:  W S K Chalmers
Journal:  Vet Microbiol       Date:  2006-04-18       Impact factor: 3.293

7.  Use of SLAM and PVRL4 and identification of pro-HB-EGF as cell entry receptors for wild type phocine distemper virus.

Authors:  Mary M Melia; John Philip Earle; Haniah Abdullah; Katherine Reaney; Frederic Tangy; Sara Louise Cosby
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

8.  Control of canine distemper.

Authors:  G Chappuis
Journal:  Vet Microbiol       Date:  1995-05       Impact factor: 3.293

Review 9.  Ferrets as a model for morbillivirus pathogenesis, complications, and vaccines.

Authors:  S Pillet; N Svitek; V von Messling
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.